Merger frenzy in the pharmaceuticals business

The record deal between Bristol-Myers Squibb and Celgene moved closer this week. The pharmaceuticals sector is rapidly consolidating. Matthew Partridge reports.

Giovanni Caforio, chief executive officer of Bristol-Myers Squibb ©  Christopher Goodney/Bloomberg via Getty Images

Giovanni Caforio: an ambitious dealmaker

The record deal between Bristol-Myers Squibb and Celgene moved closer this week. The pharmaceuticals sector is rapidly consolidating. Matthew Partridge reports

Bristol-Myers Squibb has "moved a step closer" to completing the largest takeover deal in the healthcare industry, says James Dean in The Times. Celgene, its target, has agreed to sell its blockbuster psoriasis treatment, Otezla, to Amgen for $13.4bn. Celgene first put Otezla up for sale two months ago to placate US competition regulators who were concerned that its combination with Bristol-Myers Squibb "could give the new company too much power in the market for anti-inflammatory drugs". Amgen says Otezla will cost it closer to $11.2bn owing to tax benefits.

Bristol-Myers will benefit in several ways from the deal, says Richard Beales on Breakingviews. Not only will the sale "smooth" any potential antitrust problems, but the money raised will reduce leverage at the larger company and allow it to "ratchet up its share repurchases" at the same time. Moreover, Giovanni Caforio, chairman and chief executive of Bristol-Myers, "can now breathe a sigh of relief", with his "ambitious dealmaking" having passed itsfirst test.

An overpriced pill?

However, this deal "may have bucked that trend" as Otezla has cost Amgen substantially more than expected. Indeed, one analyst from brokerage Jefferies said that $8bn "would be the benchmark for a cheap price", while another "put a $10bn high-end price on the drug".

It's true that Amgen is paying a lot, especially given the fact that Celgene is a "motivated seller", says Charley Grant in The Wall Street Journal. Still, even though Amgen has offered an "attractive amount" for the drug, its shareholders shouldn't feel too hard done by, since the evidence suggests that the biotech firm "isn't necessarily overpaying". The drug "carries relatively little risk" as Otezla is approved to treat three separate indications, and its key patents don't expire until 2028. Amgen expects "at least double-digit average sales growth over the next five years".

This transaction "is the latest in an industry that has seen a staggering amount of dealmaking this year", says the Financial Times. Indeed, "more than $700bn-worth of transactions" have been agreed in the drug and healthcare sectors this year so far.

This "frenzy" has been driven by "the desire to sell non-core assets or buy innovative medicines as [pharma firms'] own drugs are close to losing patent protection". Companies are also concentrating on becoming "one of the top three players" in their category.

Recommended

Rob Arnott: Covid's hidden investment opportunities
Investment strategy

Rob Arnott: Covid's hidden investment opportunities

Merryn talks to Rob Arnott of Research Affiliates about some of the unexpected consequences of Covid and their opportunities for investors, plus the "…
24 Sep 2021
Evergrande: Chinese property giant spooks global markets
China stockmarkets

Evergrande: Chinese property giant spooks global markets

Global markets fell this week as investors worried about the fate of Evergrande, China’s most indebted property developer, which is teetering on the b…
24 Sep 2021
Investing in football clubs: how you can profit from the beautiful game
Share tips

Investing in football clubs: how you can profit from the beautiful game

Football clubs may often be money pits for oligarchs, but they are also huge global brands, says John Chambers – and investors are now starting to rec…
24 Sep 2021
The US Federal Reserve is about to rein in its money-printing – what does that mean for markets?
US Economy

The US Federal Reserve is about to rein in its money-printing – what does that mean for markets?

America’s central bank is talking surprisingly tough about tightening monetary policy. And it’s not the only one. John Stepek looks at what it all mea…
23 Sep 2021

Most Popular

Two shipping funds to buy for steady income
Investment trusts

Two shipping funds to buy for steady income

Returns from owning ships are volatile, but these two investment trusts are trying to make the sector less risky.
7 Sep 2021
Should investors be worried about stagflation?
US Economy

Should investors be worried about stagflation?

The latest US employment data has raised the ugly spectre of “stagflation” – weak growth and high inflation. John Stepek looks at what’s going on and …
6 Sep 2021
A nightmare 1970s scenario for investors is edging closer
Investment strategy

A nightmare 1970s scenario for investors is edging closer

Inflation need not be a worry unless it is driven by labour market shortages. Unfortunately, writes macroeconomist Philip Pilkington, that’s exactly w…
17 Sep 2021